BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New Drugs Slow Metastatic Prostate Cancer


10/19/2005 5:11:46 PM

A drug used to treat advanced breast and lung cancers has been found to prolong the lives of men with advanced prostate cancer whose tumors don't respond to hormone therapy, according to two studies published on Wednesday. But treatment with docetaxel, sold by Aventis under the brand name Taxotere, is not a cure. The men who received it only lived two months longer than patients who received the Amgen drug mitoxantrone. The lead author of one of the studies, Daniel Petrylak of Columbia University, said the research shows "Taxotere is a new standard for the treatment of men with advanced prostate cancer" and the first drug to increase survival when hormone therapy doesn't work. Prostate cancer kills about 29,900 men each year in the United States and more than 230,000 are diagnosed with it each year, according to the American Cancer Society. Both studies were funded by Aventis, which is part of the Sanofi-Aventis Group, and published in the New England Journal of Medicine.

Read at Reuters
Read at HealthDay

Reuters
HealthDay
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES